Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CHRISTOPHER G WOOD and JOSE ANTONIO KARAM.
CHRISTOPHER G WOOD
Connection Strength
16.373
JOSE ANTONIO KARAM
  1. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun. 2023 05 10; 14(1):2684.
    View in: PubMed
    Score: 0.937
  2. Editorial Comment. J Urol. 2018 01; 199(1):52.
    View in: PubMed
    Score: 0.634
  3. Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial. BJU Int. 2016 Apr; 117(4):629-35.
    View in: PubMed
    Score: 0.543
  4. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol. 2014 Nov; 66(5):874-80.
    View in: PubMed
    Score: 0.493
  5. Re: Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. J Urol. 2013 Nov; 190(5):1710.
    View in: PubMed
    Score: 0.476
  6. Words of wisdom: re: prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Eur Urol. 2013 Apr; 63(4):769.
    View in: PubMed
    Score: 0.465
  7. The effects of temporary ischemia in partial nephrectomy on renal functional outcomes: how can effects best be estimated, and can they be mitigated? Eur Urol. 2012 Jul; 62(1):136-8; discussion 138-9.
    View in: PubMed
    Score: 0.432
  8. Management of small renal masses: watch, cut, freeze, or fry? Eur Urol. 2012 May; 61(5):905-6; discussion 906-7.
    View in: PubMed
    Score: 0.429
  9. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy. Hematol Oncol Clin North Am. 2011 Aug; 25(4):753-64.
    View in: PubMed
    Score: 0.414
  10. The dark side of targeted therapy. Eur Urol. 2011 Apr; 59(4):541-2.
    View in: PubMed
    Score: 0.400
  11. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur Urol. 2011 Apr; 59(4):619-28.
    View in: PubMed
    Score: 0.396
  12. Editorial comment. J Urol. 2010 Mar; 183(3):870; discussion 870.
    View in: PubMed
    Score: 0.372
  13. Urinary miRNAs Predict Metastasis in Patients With Clinically Localized Clear Cell Renal Cell Carcinoma Treated With Nephrectomy. Clin Genitourin Cancer. 2024 02; 22(1):e156-e162.e4.
    View in: PubMed
    Score: 0.241
  14. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805. BJU Int. 2022 06; 129(6):718-722.
    View in: PubMed
    Score: 0.209
  15. Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urol Oncol. 2021 12; 39(12):837.e9-837.e17.
    View in: PubMed
    Score: 0.209
  16. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol. 2021 11; 39(11):790.e17-790.e23.
    View in: PubMed
    Score: 0.207
  17. Role of lymph node dissection at the time of open or minimally invasive nephroureterectomy. Transl Androl Urol. 2021 May; 10(5):2233-2245.
    View in: PubMed
    Score: 0.204
  18. The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma. Indian J Urol. 2021 Jan-Mar; 37(1):13-19.
    View in: PubMed
    Score: 0.199
  19. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. JCI Insight. 2020 11 19; 5(22).
    View in: PubMed
    Score: 0.197
  20. Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications. Cancer. 2020 11 15; 126(22):4878-4885.
    View in: PubMed
    Score: 0.195
  21. Cytoreductive Nephrectomy in Patients Presenting With Advanced Disease: Have We Finally Answered the Question? Cancer J. 2020 Sep/Oct; 26(5):382-389.
    View in: PubMed
    Score: 0.194
  22. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU Int. 2020 12; 126(6):745-753.
    View in: PubMed
    Score: 0.194
  23. Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma. Urol Clin North Am. 2020 Aug; 47(3):329-343.
    View in: PubMed
    Score: 0.191
  24. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer. 2020 09 01; 126(17):3950-3960.
    View in: PubMed
    Score: 0.191
  25. EDITORIAL COMMENT. Urology. 2020 02; 136:175.
    View in: PubMed
    Score: 0.187
  26. Predicting Adherent Perinephric Fat Using Preoperative Clinical and Radiological Factors in Patients Undergoing Partial Nephrectomy. Eur Urol Focus. 2021 03; 7(2):397-403.
    View in: PubMed
    Score: 0.183
  27. Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging. Cancer. 2018 10 15; 124(20):4023-4031.
    View in: PubMed
    Score: 0.170
  28. Adjuvant therapy for advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2018 07; 18(7):663-671.
    View in: PubMed
    Score: 0.165
  29. Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes. Urology. 2018 Jun; 116:114-119.
    View in: PubMed
    Score: 0.164
  30. Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience. World J Urol. 2018 Jul; 36(7):1093-1101.
    View in: PubMed
    Score: 0.163
  31. Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review. Kidney Cancer. 2017 Nov 27; 1(2):115-121.
    View in: PubMed
    Score: 0.161
  32. Local Tumor Bed Recurrence Following Partial Nephrectomy in Patients with Small Renal Masses. J Urol. 2018 02; 199(2):393-400.
    View in: PubMed
    Score: 0.158
  33. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017 Dec 15; 123(24):4823-4831.
    View in: PubMed
    Score: 0.158
  34. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017 08; 198(2):281-288.
    View in: PubMed
    Score: 0.153
  35. Study of the Kidney Tumor-Parenchymal Interface after Neoadjuvant Treatment with Axitinib for Locally Advanced Clear Cell Renal Cell Carcinoma: Matched Analysis from a Phase II Trial. J Urol. 2017 03; 197(3 Pt 1):559-565.
    View in: PubMed
    Score: 0.148
  36. Cytoreductive nephrectomy for metastatic renal cell carcinoma. Clin Adv Hematol Oncol. 2016 Sep; 14(9):696-703.
    View in: PubMed
    Score: 0.147
  37. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol. 2016 Sep; 196(3):678-84.
    View in: PubMed
    Score: 0.143
  38. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol. 2016 May; 34(5):237.e19-26.
    View in: PubMed
    Score: 0.140
  39. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol. 2016 Apr; 8(2):130-41.
    View in: PubMed
    Score: 0.140
  40. Surgical considerations for patients with metastatic renal cell carcinoma. Urol Oncol. 2015 Dec; 33(12):528-37.
    View in: PubMed
    Score: 0.139
  41. Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis. BJU Int. 2016 Jun; 117(6B):E87-94.
    View in: PubMed
    Score: 0.138
  42. Role of metastasectomy in metastatic renal cell carcinoma. Curr Opin Urol. 2015 Sep; 25(5):381-9.
    View in: PubMed
    Score: 0.137
  43. Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre. BJU Int. 2016 May; 117(5):775-82.
    View in: PubMed
    Score: 0.136
  44. Cytoreductive surgery in the era of targeted molecular therapy. Transl Androl Urol. 2015 Jun; 4(3):301-9.
    View in: PubMed
    Score: 0.135
  45. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015 Oct; 33(10):427.e17-23.
    View in: PubMed
    Score: 0.135
  46. Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes. BJU Int. 2015 Jul; 116(1):85-92.
    View in: PubMed
    Score: 0.133
  47. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol. 2015 Aug; 194(2):316-22.
    View in: PubMed
    Score: 0.133
  48. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol. 2015 Apr; 33(4):166.e21-9.
    View in: PubMed
    Score: 0.132
  49. Salvage surgery after energy ablation for renal masses. BJU Int. 2015 Jan; 115(1):74-80.
    View in: PubMed
    Score: 0.131
  50. Reporting geographic and temporal trends in renal cell carcinoma: why is this important? Eur Urol. 2015 Mar; 67(3):531-2.
    View in: PubMed
    Score: 0.130
  51. Preoperative predictors of pathological lymph node metastasis in patients with renal cell carcinoma undergoing retroperitoneal lymph node dissection. J Urol. 2015 Apr; 193(4):1101-7.
    View in: PubMed
    Score: 0.130
  52. Lymphatic drainage in renal cell carcinoma: back to the basics. BJU Int. 2014 Dec; 114(6):806-17.
    View in: PubMed
    Score: 0.128
  53. Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. World J Urol. 2014 Jun; 32(3):631-42.
    View in: PubMed
    Score: 0.125
  54. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era. Urol Oncol. 2014 Jul; 32(5):561-8.
    View in: PubMed
    Score: 0.125
  55. Positive vascular wall margins have minimal impact on cancer outcomes in patients with non-metastatic renal cell carcinoma (RCC) with tumour thrombus. BJU Int. 2014 Nov; 114(5):667-73.
    View in: PubMed
    Score: 0.124
  56. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol. 2014 Jul; 192(1):36-42.
    View in: PubMed
    Score: 0.123
  57. Treating the two extremes in renal cell carcinoma: management of small renal masses and cytoreductive nephrectomy in metastatic disease. Am Soc Clin Oncol Educ Book. 2014; e214-21.
    View in: PubMed
    Score: 0.122
  58. Biomarkers of renal cell carcinoma. Urol Oncol. 2014 Apr; 32(3):243-51.
    View in: PubMed
    Score: 0.121
  59. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int. 2013 May; 111(6):997-1005.
    View in: PubMed
    Score: 0.116
  60. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011 Feb; 185(2):439-44.
    View in: PubMed
    Score: 0.099
  61. Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol. 2010 Nov; 184(5):1882-7.
    View in: PubMed
    Score: 0.097
  62. Contemporary Patients Have Better Perioperative Outcomes Following Cytoreductive Nephrectomy: A Multi-institutional Analysis of 1272 Consecutive Patients. Urology. 2023 12; 182:168-174.
    View in: PubMed
    Score: 0.060
  63. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus. 2023 09; 9(5):734-741.
    View in: PubMed
    Score: 0.058
  64. Predictive capacity of a miRNA panel in identifying teratoma in post-chemotherapy consolidation surgeries. BJUI Compass. 2023 Jan; 4(1):81-87.
    View in: PubMed
    Score: 0.055
  65. PET/MR Imaging of a Lung Metastasis Model of Clear Cell Renal Cell Carcinoma with (2S,4R)-4-[18F]Fluoroglutamine. Mol Imaging Biol. 2022 12; 24(6):959-972.
    View in: PubMed
    Score: 0.055
  66. Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. J Clin Endocrinol Metab. 2022 04 19; 107(5):1239-1246.
    View in: PubMed
    Score: 0.054
  67. Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. Cancers (Basel). 2022 Feb 23; 14(5).
    View in: PubMed
    Score: 0.054
  68. Lymphangioembolization for iatrogenic chylous ascites after retroperitoneal urological surgery. BJU Int. 2022 05; 129(5):585-587.
    View in: PubMed
    Score: 0.054
  69. A generative adversarial approach to facilitate archival-quality histopathologic diagnoses from frozen tissue sections. Lab Invest. 2022 05; 102(5):554-559.
    View in: PubMed
    Score: 0.053
  70. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel). 2021 Nov 30; 13(23).
    View in: PubMed
    Score: 0.053
  71. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375.
    View in: PubMed
    Score: 0.053
  72. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer. 2021 12; 19(6):e401-e408.
    View in: PubMed
    Score: 0.052
  73. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. 2022 05; 129(5):610-620.
    View in: PubMed
    Score: 0.052
  74. Correction: Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2021 Jun 01; 27(11):3265.
    View in: PubMed
    Score: 0.051
  75. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel). 2021 Apr 30; 13(9).
    View in: PubMed
    Score: 0.051
  76. Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies. AJR Am J Roentgenol. 2021 07; 217(1):157-163.
    View in: PubMed
    Score: 0.051
  77. Prolyl Hydroxylase 3 Knockdown Accelerates VHL-Mutant Kidney Cancer Growth In Vivo. Int J Mol Sci. 2021 Mar 11; 22(6).
    View in: PubMed
    Score: 0.050
  78. Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor. Cancers (Basel). 2020 Dec 14; 12(12).
    View in: PubMed
    Score: 0.050
  79. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 02; 39(2):134.e9-134.e16.
    View in: PubMed
    Score: 0.049
  80. Macrophage HIF-1a Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2020 09 15; 26(18):4970-4982.
    View in: PubMed
    Score: 0.048
  81. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell. 2020 05 11; 37(5):720-734.e13.
    View in: PubMed
    Score: 0.047
  82. Stereotactic Body Radiation Therapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison With Surgery, Tumor Ablation, and Observation. Adv Radiat Oncol. 2020 May-Jun; 5(3):495-502.
    View in: PubMed
    Score: 0.047
  83. PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. Urol Oncol. 2020 05; 38(5):496-505.
    View in: PubMed
    Score: 0.046
  84. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. Eur Urol Oncol. 2020 10; 3(5):687-694.
    View in: PubMed
    Score: 0.045
  85. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019 11; 32(11):1698-1707.
    View in: PubMed
    Score: 0.045
  86. Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. Angew Chem Int Ed Engl. 2019 03 22; 58(13):4179-4183.
    View in: PubMed
    Score: 0.044
  87. Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2019 Nov; 37(11):2419-2427.
    View in: PubMed
    Score: 0.044
  88. Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence. Am J Pathol. 2018 11; 188(11):2487-2496.
    View in: PubMed
    Score: 0.042
  89. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. Eur Urol Focus. 2020 01 15; 6(1):104-111.
    View in: PubMed
    Score: 0.042
  90. Conditional survival of patients with small renal masses undergoing active surveillance. BJU Int. 2019 03; 123(3):447-455.
    View in: PubMed
    Score: 0.042
  91. Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Ann Surg. 2018 07; 268(1):172-178.
    View in: PubMed
    Score: 0.042
  92. Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis. 2018 05 28; 39(6):752-757.
    View in: PubMed
    Score: 0.042
  93. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol. 2018 Dec; 36(12):2027-2034.
    View in: PubMed
    Score: 0.042
  94. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urol Oncol. 2018 Jul; 36(7):343.e1-343.e8.
    View in: PubMed
    Score: 0.041
  95. Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration. Clin Genitourin Cancer. 2018 04; 16(2):e443-e450.
    View in: PubMed
    Score: 0.040
  96. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol. 2017 09; 31(9):946-953.
    View in: PubMed
    Score: 0.039
  97. Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. J Urol. 2017 12; 198(6):1269-1277.
    View in: PubMed
    Score: 0.039
  98. The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma. Urology. 2017 10; 108:114-121.
    View in: PubMed
    Score: 0.039
  99. Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2017 12; 198(6):1253-1262.
    View in: PubMed
    Score: 0.039
  100. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma. Cancer. 2017 Sep 15; 123(18):3617-3627.
    View in: PubMed
    Score: 0.039
  101. Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. J Urol. 2017 10; 198(4):810-816.
    View in: PubMed
    Score: 0.038
  102. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol. 2017 09; 198(3):530-537.
    View in: PubMed
    Score: 0.038
  103. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. 2017 06; 15(3):363-370.
    View in: PubMed
    Score: 0.038
  104. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 2016 Dec 27; 7(52):86280-86289.
    View in: PubMed
    Score: 0.038
  105. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792.
    View in: PubMed
    Score: 0.038
  106. Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2017 Jul; 35(7):1073-1080.
    View in: PubMed
    Score: 0.037
  107. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World J Urol. 2017 Feb; 35(2):251-259.
    View in: PubMed
    Score: 0.036
  108. DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. Clin Cancer Res. 2016 Dec 15; 22(24):6236-6246.
    View in: PubMed
    Score: 0.036
  109. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World J Urol. 2017 Jan; 35(1):121-130.
    View in: PubMed
    Score: 0.036
  110. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2017 Jan; 35(1):113-120.
    View in: PubMed
    Score: 0.036
  111. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43.
    View in: PubMed
    Score: 0.036
  112. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol. 2016 08; 70(2):348-57.
    View in: PubMed
    Score: 0.035
  113. Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study. Clin Cancer Res. 2016 Apr 15; 22(8):2074-82.
    View in: PubMed
    Score: 0.035
  114. Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World J Urol. 2016 Aug; 34(8):1155-61.
    View in: PubMed
    Score: 0.035
  115. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74.
    View in: PubMed
    Score: 0.035
  116. Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma. Cancer. 2016 Jan 01; 122(1):108-15.
    View in: PubMed
    Score: 0.035
  117. Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules. Eur Urol. 2016 Feb; 69(2):352-60.
    View in: PubMed
    Score: 0.034
  118. Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol. 2015 Nov; 33(11):495.e15-22.
    View in: PubMed
    Score: 0.034
  119. Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res. 2015 Oct; 1(4):212-24.
    View in: PubMed
    Score: 0.034
  120. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 May; 117(5):761-5.
    View in: PubMed
    Score: 0.034
  121. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol. 2015 Sep; 28(9):1225-35.
    View in: PubMed
    Score: 0.034
  122. Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract. J Urol. 2015 May; 193(5):1486-93.
    View in: PubMed
    Score: 0.032
  123. Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma. Urology. 2014 Nov; 84(5):1134-40.
    View in: PubMed
    Score: 0.032
  124. Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. Eur Urol. 2014 Aug; 66(2):379-85.
    View in: PubMed
    Score: 0.031
  125. Robotic partial nephrectomy shortens warm ischemia time, reducing suturing time kinetics even for an experienced laparoscopic surgeon: a comparative analysis. World J Urol. 2014 Feb; 32(1):265-71.
    View in: PubMed
    Score: 0.030
  126. Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. Eur Urol. 2013 Jun; 63(6):1122-7.
    View in: PubMed
    Score: 0.029
  127. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011 Jun; 59(6):912-8.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.